公开(公告)号：KR101236297B1

公开(公告)日：2013-02-22

申请号：KR1020090109938

申请日：2009-11-13

Applicant: 한국식품연구원

Inventor： 김혜영 ,  김동현 ,  이영경 ,  한찬규 ,  황진택 ,  이영철 ,  민성원 ,  김경 ,  박민

IPC: C12N1/20 ,  A23L19/00 ,  A23L2/72

Abstract: 본 발명은 신규한 엔테로코커스 패칼리스 케이-60 균주(Enterococcus faecalis K-60)(KFCC11460P)(이하 K-60으로 약칭한다) 및 상기 균주를 이용한 포도당 항상성 개선용 인삼 발효 추출물 및 그의 제조방법에 관한 것으로서 보다 상세하게는 인삼을 발효시킬 수 있는 신규한 K-60 및 상기 균주로 인삼을 발효시켜 포도당 항상성 개선에 적용할 수 있는 인삼 발효 추출물 및 이의 제조방법에 관한 것이다.
본 발명의 인삼을 엔테로코커스 패칼리스 케이-60 균주로 발효시켜 얻은 발효 추출물은 포도당 항상성 유지 혹은 개선 효과가 우수하여 공복혈당장애자, 내당능장애자, 당뇨병 전단계로 진단받은 자 및 당뇨병 환자의 치료에 효과가 있다.
엔테로코커스 패칼리스 케이-60, 인삼 발효, 포도당 항상성, 당뇨병, 혈당강하

公开(公告)号：KR101151295B1

公开(公告)日：2012-06-19

申请号：KR1020090109947

申请日：2009-11-13

Applicant: 한국식품연구원

Inventor： 김혜영 ,  김동현 ,  이영경 ,  한찬규 ,  황진택 ,  이영철 ,  민성원 ,  김경 ,  박민

IPC: C12N1/20 ,  A23L19/00 ,  A23L2/72

Abstract: PURPOSE: A Pediococcus pentosaceus K-641(KFCC11463P) is provided to convert ginsenoside of low bioavailability to ginsenoside of high bioavailability and to improve glucose homeostasis. CONSTITUTION: A novel Pediococcus pentosaceus K-641(KFCC11463P) is used for fermenting ginseng. A method for preparing ginseng fermentation extract comprises: a step of fermenting a suspension of ginseng power with Pediococcus pentosaceus K-641(KFCC11463P) at 35-37 degrees Celsius for 3-10 days to obtain a fermentation; a step of extracting the fermentation with a solvent of ethanol, spirit, or butanol; and a step of filtering the extract.

公开(公告)号：KR1020120061017A

公开(公告)日：2012-06-12

申请号：KR1020100109052

申请日：2010-11-04

Applicant: 한국식품연구원

Inventor： 권대영 ,  성미정 ,  황진택 ,  박재호 ,  양혜정 ,  허행전 ,  김현진 ,  김명선

IPC: A61K31/26 ,  A61P3/04 ,  A61P3/06 ,  A61P3/00

Abstract: PURPOSE: A pharmaceutical composition and health functional food containing thienylbutyl isothiocyanate are provided to inhibit adipocyte differentiation. CONSTITUTION: A pharmaceutical composition for preventing and treating obesity and lipid-related metabolic disorders contains 0.1-50 wt% of thienylbutyl isothiocyanate as an active ingredient. The composition is administered in 0.01-500 mg/kg. The composition is manufactured in the form of powder, granules, tablets, capsules, suspension, emulsion, syrup, oral administration, external use formulation, suppository, or sterilized injection solution. A health functional for preventing and relieving obesity and lipid-related metabolic diseases contains the thienyl butyl isothiocyanate as an active ingredient. The health functional food is manufactured in the form of capsules, tablets, granules, powder, or beverage.

Abstract translation: 目的：提供含有噻吩基丁基异硫氰酸酯的药物组合物和保健功能食品，以抑制脂肪细胞分化。 构成：用于预防和治疗肥胖症和与脂质有关的代谢紊乱的药物组合物含有0.1-50重量％的异硫氰酸噻吩基丁酯作为活性成分。 组合物以0.01-500mg / kg施用。 组合物以粉末，颗粒，片剂，胶囊，悬浮液，乳剂，糖浆，口服给药，外用制剂，栓剂或灭菌注射液的形式制造。 用于预防和减轻肥胖症和脂质相关代谢疾病的健康功能包含异硫氰酸噻吩基丁酯作为活性成分。 保健功能食品以胶囊，片剂，颗粒，粉末或饮料的形式制造。

公开(公告)号：KR1020120017912A

公开(公告)日：2012-02-29

申请号：KR1020100080863

申请日：2010-08-20

Applicant: 한국식품연구원

Inventor： 윤석후 ,  권대영 ,  김현진 ,  박재호 ,  양혜정 ,  김명선 ,  황진택 ,  허행전 ,  성미정 ,  고성호 ,  김진희 ,  노시원

IPC: G01N33/50 ,  G01N33/68 ,  G01N33/66 ,  G01N33/92

Abstract: PURPOSE: A method for detecting a marker contained in a biological sample is provided to diagnose and treat obesity or obesity-associated diseases. CONSTITUTION: A method for detecting a marker contained in a biological sample for diagnosing obesity comprises a step of detecting the concentration of arginine, tyrosine, pipecolic acid, benzoic acid, pantothenic acid, uric acid, phenyl acetamide, serotonin, L-carnitine, decanoyl carnitine, myristoyl carnitine, hexadekenoyl carnitine, linoleyl carnitien, vacenyl carnitine, stearoyl carnitine, lysoPC(C14:0), lysoPC(C15:0), lysoPC(C16:0), lysoPC(C16:1), lysoPC(C17:0), lysoPC(C17:1), lysoPC(C18:0), lysoPC(C18:1), lysoPC(C18:2), lysoPC(C18:3), lysoPC(C19:0), lysoPC(C20:1), lysoPC(C20:4), lysoPC(C20:5), lysoPE(C18:2), lysoPE(C20:4) or PCs marker in blood or glucose, glycerol, tyrosine, valine, 7-ketodeoxy cholic acid, and betain, L-carnitine, plamitic acid, linoleic acid, oleic acid, stearic acid, lysoPC(C14:0), lysoPC(C16:0), lysoPC(C16:1), lysoPC(C18:0), lysoPC(C18:3), lysoPC(C20:4), lysoPC(C22:6), or PCs in liver tissue.

Abstract translation: 目的：提供一种用于检测生物样品中包含的标记物的方法，用于诊断和治疗肥胖或肥胖相关疾病。 构成：用于检测用于诊断肥胖的生物样品中所含的标记物的方法包括检测精氨酸，酪氨酸，哌可酸，苯甲酸，泛酸，尿酸，苯乙酰胺，5-羟色胺，L-肉毒碱，癸酰基 肉毒碱，肉豆蔻肉碱，六酰基肉碱，亚油酰肉碱，肉桂碱肉碱，硬脂酰肉碱，溶血糖（C14：0），溶血卵磷脂（C15：0），溶血卵磷脂（C16：0），溶血卵磷脂（C16： ），lysoPC（C17：1），lysoPC（C18：0），lysoPC（C18：1），lysoPC（C18：1），lysoPC（C18：2），lysoPC（C18：3） ，血液或葡萄糖，甘油，酪氨酸，缬氨酸，7-酮基脱氧胆酸和甜菜碱中的溶血卵磷脂（C20：4），溶血卵磷脂（C20：5），溶血蛋白（C18：2），溶血蛋白（C20：4） ，L-carnitine，plamitic acid，亚油酸，油酸，硬脂酸，lysoPC（C14：0），lysoPC（C16：0），lysoPC（C16：1），lysoPC（C18：0），lysoPC（C18：3 ），溶血卵磷脂（C20：4），溶血卵磷脂（C22：6）或肝组织中的PC。

公开(公告)号：KR1020120003778A

公开(公告)日：2012-01-11

申请号：KR1020100064563

申请日：2010-07-05

Applicant: 한국식품연구원

Inventor： 황진택 ,  권대영 ,  성미정 ,  박재호 ,  양혜정 ,  김명선 ,  김현진 ,  허행전 ,  김영섭 ,  유시용

IPC: A61K36/66 ,  A61P3/04 ,  A61P3/00

CPC classification number: A61K36/66 ,  A61K2236/33 ,  Y10S514/909

Abstract: PURPOSE: A composition containing Chelidonium majus var asiaticum extract is provided to activate AMPK(5'AMP-activated protein kinase) and to ensure antiobesity. CONSTITUTION: A composition for preventing and treating obesity contains 0.1-99.9 wt% of Chelidonium majus var asiaticum extract as an active ingredient. The composition is a pharmaceutical composition or food additive composition. The food composition for preventing and treating obesity contains the extract as an active ingredient. The extract is a hot water extract or ethanol extract. The composition is manufactured in the form of beverage, gum, tea, vitamin complex, pill, powder, granule, tablet, or capsule.

Abstract translation: 目的：提供含有Chelidonium majus var asiaticum提取物的组合物以激活AMPK（5'AMP-活化的蛋白激酶）并确保抗肥胖。 构成：用于预防和治疗肥胖症的组合物含有0.1-99.9wt％的Chelidonium majus var asiaticum提取物作为活性成分。 该组合物是药物组合物或食品添加剂组合物。 用于预防和治疗肥胖症的食物组合物含有提取物作为活性成分。 提取物是热水提取物或乙醇提取物。 该组合物以饮料，口香糖，茶叶，维生素复合物，丸剂，粉末，颗粒，片剂或胶囊的形式制成。

公开(公告)号：KR1020110136215A

公开(公告)日：2011-12-21

申请号：KR1020100056077

申请日：2010-06-14

Applicant: 한국식품연구원

Inventor： 권대영 ,  성미정 ,  황진택 ,  박재호 ,  양혜정 ,  김명선 ,  김현진 ,  허행전

IPC: A61K31/52 ,  A61P3/04 ,  A61P3/00

CPC classification number: A61K31/52 ,  A23L33/10 ,  Y10S514/824 ,  Y10S514/866 ,  Y10S514/909

Abstract: PURPOSE: A composition containing 3-methyladenine is provided to decompose neutral lipid into glycerol and free fatty acid and to prevent or treat obesity, diabetes, and hyperlipidemia. CONSTITUTION: A pharmaceutical composition for preventing or treating obesity contains 3-methyladenien as an active ingredient. 3-methyladenine decomposes neutral lipid into glycerol and free fatty acid. A food composition for preventing or treating obesity contains 3-methyladenine as an active ingredient. The composition is used for preventing or treating obesity-associated metabolic diseases including diabetes, arteriosclerosis, metabolic diseases, and hyperlipidemia. The pharmaceutical composition is manufactured in the form of a liquid formulation or parenteral formulation.

Abstract translation: 目的：提供含有3-甲基腺嘌呤的组合物，以将中性脂质分解为甘油和游离脂肪酸，并预防或治疗肥胖，糖尿病和高脂血症。 构成：用于预防或治疗肥胖症的药物组合物含有3-甲基腺嘌呤作为活性成分。 3-甲基腺嘌呤将中性脂质分解成甘油和游离脂肪酸。 用于预防或治疗肥胖症的食物组合物含有3-甲基腺嘌呤作为活性成分。 该组合物用于预防或治疗肥胖相关代谢疾病，包括糖尿病，动脉硬化，代谢疾病和高脂血症。 药物组合物以液体制剂或肠胃外制剂的形式制备。

公开(公告)号：KR1020110135706A

公开(公告)日：2011-12-19

申请号：KR1020100055579

申请日：2010-06-11

Applicant: 한국식품연구원

Inventor： 권대영 ,  성미정 ,  황진택 ,  박재호 ,  양혜정 ,  김명선

IPC: A61K31/352 ,  A61K36/48 ,  A61P9/10 ,  A61P9/00

Abstract: PURPOSE: A composition containing genistein or pharmacologically acceptable salt thereof is provided to suppress fractalkine expression and vascular inflammation. CONSTITUTION: A composition for treating vasculitis caused by fractalkine expression contains 1-10 wt% of genistein or pharmacologically acceptable salt thereof as an active ingredient. The composition is a pharmaceutical composition or food additive composition. The composition also contains NF-kappaB inhibitor and p38 inhibitor or PI3'-K inhibitor in a weight ratio of 1:10-10:1.

Abstract translation: 目的：提供含有染料木素或其药理学上可接受的盐的组合物以抑制分裂素表达和血管炎症。 构成：用于治疗由fractalkine表达引起的血管炎的组合物含有1-10重量％的染料木黄酮或其药理学上可接受的盐作为活性成分。 该组合物是药物组合物或食品添加剂组合物。 组合物还含有重量比为1:10-10:1的NF-κB抑制剂和p38抑制剂或PI3'-K抑制剂。

公开(公告)号：KR101072834B1

公开(公告)日：2011-10-14

申请号：KR1020070138273

申请日：2007-12-27

Applicant: 한국식품연구원

Inventor： 이영철 ,  김혜영 ,  노정해 ,  이영경 ,  황진택 ,  조장원 ,  김경 ,  박민

IPC: A61K36/258 ,  A61K36/074 ,  A61P3/10

Abstract: 본발명은인삼을영지버섯(Ganoderma lucidum KCTC 6532) 균사체로발효시켜서제조된혈당강하용다당체분획물에관한것으로서, 상기혈당강하용다당체분획물은인삼을영지버섯균사체로발효하는단계; 발효물을증류수로열수추출한후 여과하는단계및 여과액과주정을혼합하여다당체분획물의침전물을얻는단계를거쳐제조된다. 이다당체분획물은혈당강하효과가우수하여공복혈당장애자, 내당능장애자, 당뇨병전단계로진단받은자, 당뇨병환자의치료에효과가있다.

公开(公告)号：KR1020110058515A

公开(公告)日：2011-06-01

申请号：KR1020090115334

申请日：2009-11-26

Applicant: 한국식품연구원

Inventor： 김혜영 ,  김동현 ,  이영경 ,  한찬규 ,  황진택 ,  이영철 ,  민성원 ,  김경 ,  박민

IPC: C12N1/20 ,  C12P1/04 ,  A61K31/70 ,  A23L19/00

Abstract: PURPOSE: A ginseng fermentation extract using a novel Pediococcus pentosaceus K-51 is provided to enhance insulin secretion and to treat diabetes. CONSTITUTION: A novel Pediococcus pentosaceus K-51(KFCC11465P) is able to ferment ginseng. A method for preparing a ginseng fermentation extract comprises: a step of fermenting ginseng powder with Pediococcus pentosaceus K-51(KFCC11465P) at 35-37 degrees Celsius for 3-10 days to obtain fermentation; and a step of filtering the fermentation using ethanol, spirit, or butanol at 60-80 degrees Celsius for 2-4 hours. A pharmaceutical formulation for enhancing insulin secretion contains the ginseng fermentation extract.

Abstract translation: 目的：提供一种人参发酵提取物，使用新型戊糖片球菌K-51来增强胰岛素分泌和治疗糖尿病。 构成：一种新型戊糖片球菌K-51（KFCC11465P）能够发酵人参。 制备人参发酵提取物的方法包括：在35-37摄氏度下将人参粉末与戊糖片球菌K-51（KFCC11465P）发酵3-10天以获得发酵的步骤; 以及在60-80摄氏度下使用乙醇，精油或丁醇过滤发酵2-4小时的步骤。 用于增强胰岛素分泌的药物制剂含有人参发酵提取物。

公开(公告)号：KR1020110053116A

公开(公告)日：2011-05-19

申请号：KR1020090109942

申请日：2009-11-13

Applicant: 한국식품연구원

Inventor： 김혜영 ,  김동현 ,  이영경 ,  한찬규 ,  황진택 ,  이영철 ,  민성원 ,  김경 ,  박민

IPC: C12N1/20 ,  A23L19/00 ,  A23L2/72

Abstract: PURPOSE: A novel Pediococcus pentosaceus K-65(KFCC11462P) and a method for preparing a ginseng fermentation using the same are provided to improve and maintain glucose homeostasis. CONSTITUTION: A novel Pediococcus pentosaceus K-65(KFCC11462P) is used for fermenting ginseng. A method for preparing ginseng fermentation extract comprises: a step of fermenting ginseng with Pediococcus pentosaceus K-65(KFCC11462P) at 35-37°C for 3-10 days to obtain a fermentation; a step of extracting with a solvent such as ethanol, spirit, or butanol at 60°C-80°C for 2-4 hours; and a step of filtering the extract. A pharmaceutical composition or health food for maintaining or improving glucose homeostasis contains the ginseng fermentation extract.

Abstract translation: 目的：提供一种新型戊糖片球菌K-65（KFCC11462P）及其制备人参发酵方法，以改善和维持葡萄糖体内平衡。 构成：一种新型戊酸球菌K-65（KFCC11462P）用于发酵人参。 一种人参发酵提取物的制备方法，其特征在于：在35-37℃下将戊糖片球菌K-65（KFCC11462P）人参发酵3-10天，得到发酵的步骤; 用溶剂如乙醇，精油或丁醇在60℃-80℃下萃取2-4小时的步骤; 以及过滤提取物的步骤。 用于维持或改善葡萄糖体内平衡的药物组合物或保健食品含有人参发酵提取物。